Essa Pharma Inc. Announces US$80 Million Cash Distribution to Shareholders

Core Viewpoint - ESSA Pharma Inc. has announced a return of capital distribution amounting to US$80 million to its shareholders as part of the winding-up of the company's business following a court order [1][3]. Group 1: Distribution Details - The distribution is scheduled to be paid on August 22, 2025, to shareholders of record as of the close of business on August 19, 2025 [2]. - Each shareholder is estimated to receive approximately US$1.91 per common share, excluding any contingent value rights payments related to the transaction with XenoTherapeutics, Inc. [4]. Group 2: Transaction with XenoTherapeutics - The distribution will occur prior to a special meeting of shareholders, optionholders, and warrantholders to consider the transaction with XenoTherapeutics, which is expected to be held on September 10, 2025 [3]. - The company obtained an interim court order on August 5, 2025, authorizing the special meeting [3]. Group 3: Company Background - ESSA Pharma Inc. is a pharmaceutical company that previously focused on developing novel therapies for prostate cancer [5].